ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization,
Part 4 – Biological Products

Part 4 – Biological Products

COVID-19 Vaccines

COVID-19 mRNA Vaccine COMIRNATY™ (Pfizer-BioNTech)
Per Provincial Health Officer direction, the minimum interval between completion of the primary series and the booster dose has been revised from 28 days to 8 weeks. This is reflected in the footnotes within the Doses and Schedule and Booster Doses sections.

Please remove page numbers: 1-6 dated October 28, 2021
Please add new page numbers: 1-6 dated October 29, 2021

COVID-19 mRNA Vaccine SPIKEVAX™ (Moderna)
Per Provincial Health Officer direction, the following revisions have been made:

- Doses and Schedule:
  - The booster dose has been revised to 0.5 mL for all eligible individuals.
  - The minimum interval between completion of the primary series and the booster dose has been revised from 28 days to 8 weeks. This is also reflected in the footnotes within the Booster Doses section.

Please remove page numbers: 1-6 dated October 28, 2021
Please add new page numbers: 1-5 dated October 29, 2021

COVID-19 Vaccine VAXZEVRIA™/COVISHIELD (AstraZeneca/Verity Pharmaceuticals)
Per Provincial Health Officer direction, the minimum interval between completion of the primary series and the booster dose has been revised from 28 days to 8 weeks. This is reflected in the footnotes within the Booster Doses section.

Please remove page numbers: 1-5 dated October 28, 2021
Please add new page numbers: 1-5 dated October 29, 2021
COVID-19 Vaccine (Ad26.COV2.S [recombinant]) (Janssen Inc.)

Per Provincial Health Officer direction, the minimum interval between completion of the primary series and the booster dose has been revised from 28 days to 8 weeks. This is reflected in the footnotes within the Booster Doses section.

Please remove page numbers: 1-5 dated October 28, 2021
Please add new page numbers: 1-5 dated October 29, 2021

If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,

Monika Naus MD MHSc FRCPC FACPM
Medical Director
Communicable Diseases & Immunization Service
BC Centre for Disease Control

Provincial Health Officer
Dr. Bonnie Henry

Dr. Reka Gustafson
Vice President, Public Health & Wellness, PHSA & Deputy Provincial Health Officer

Deputy Provincial Health Officer
Dr. Martin Lavoie

pc:

BC Ministry of Health, Population & Public Health Division:

Brian Sagar
Senior Director Communicable Disease, Population and Public Health Division

Bernard Achampong
Executive Director, Public Health, Planning and Prevention, Population and Public Health Division